Zymeworks (ZYME)Chief Scientific Officer sold ~$170K

~$170K

Approx. value · 11K sh @ $14.92

23K

Holds after · shares reported

Traded

Jan 6, 2025

Filed

Jan 7, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Dec 19, 2024InsiderDirector purchased ~$4.04M of ZYME shares in the open market
2. Dec 20, 2024InsiderDirector purchased ~$9.92M of ZYME shares in the open market
3. Dec 23, 2024InsiderDirector purchased ~$3.58M of ZYME shares in the open market
4. Dec 24, 2024InsiderDirector purchased ~$169K of ZYME shares in the open market
5. Dec 26, 2024InsiderDirector purchased ~$240K of ZYME shares in the open market
6. Dec 27, 2024InsiderDirector purchased ~$1.47M of ZYME shares in the open market
7. Dec 30, 2024InsiderDirector purchased ~$853K of ZYME shares in the open market
8. Dec 31, 2024InsiderDirector purchased ~$2.13M of ZYME shares in the open market
9. Jan 2, 2025InsiderDirector purchased ~$2.33M of ZYME shares in the open market
10. Jan 6, 2025 · this disclosureInsiderOfficer sold ~$170K of ZYME shares in the open market

What came next

1. Jan 6, 2025Insider · 3 peopleInsiders: 4 sales (~$1.2M)
2. Jan 8, 2025InsiderDirector purchased ~$296K of ZYME shares in the open market
3. Jan 10, 2025InsiderDirector purchased ~$2.68M of ZYME shares in the open market
4. Jan 13, 2025InsiderDirector purchased ~$993K of ZYME shares in the open market
5. Jan 14, 2025InsiderDirector purchased ~$739K of ZYME shares in the open market
6. Jan 15, 2025InsiderDirector purchased ~$547K of ZYME shares in the open market
7. Jan 16, 2025InsiderDirector purchased ~$1.69M of ZYME shares in the open market
8. Jan 17, 2025InsiderDirector purchased ~$274K of ZYME shares in the open market
9. Mar 11, 2025InsiderDirector purchased ~$3.69M of ZYME shares in the open market
10. Mar 12, 2025InsiderDirector purchased ~$3.59M of ZYME shares in the open market
11. Mar 13, 2025InsiderDirector purchased ~$5.85M of ZYME shares in the open market
12. Mar 17, 2025InsiderDirector purchased ~$688K of ZYME shares in the open market
13. Mar 18, 2025InsiderDirector purchased ~$1.44M of ZYME shares in the open market
14. Mar 19, 2025InsiderDirector purchased ~$737K of ZYME shares in the open market
15. Mar 20, 2025InsiderDirector purchased ~$950K of ZYME shares in the open market
16. Mar 21, 2025InsiderDirector purchased ~$397K of ZYME shares in the open market
17. Mar 24, 2025InsiderDirector purchased ~$297K of ZYME shares in the open market
18. Mar 25, 2025InsiderDirector purchased ~$690K of ZYME shares in the open market
19. Mar 26, 2025InsiderDirector purchased ~$537K of ZYME shares in the open market
20. Mar 31, 2025InsiderDirector purchased ~$52K of ZYME shares in the open market

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Zymeworks

For Zymeworks, OQRO holds 2 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ZYME page.

Other recent filings by Paul Andrew Moore, Chief Scientific Officer

• SEC Form 4 at Zymeworks (ZYME)Jan 7, 2025

The full history of Paul Andrew Moore, Chief Scientific Officer is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Zymeworks

• SEC Form 144Oct 9, 2026
• SEC Form 4Oct 9, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRMay 29, 2026
• SEC Form 13F-HRMay 15, 2026
• SEC Form 13F-HRMay 14, 2026

Everything OQRO holds on this company is on its ZYME page.